{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:47:30Z","timestamp":1766087250523},"reference-count":32,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.10.028","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T15:33:07Z","timestamp":1508772787000},"page":"6657-6663","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"PB","title":["Reactogenicity and safety assessment of an attenuated nanovaccine against scorpion envenomation: Preclinical study"],"prefix":"10.1016","volume":"35","author":[{"given":"Faez Amokrane","family":"Nait Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelmounaim","family":"Nouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Laraba-Djebari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.10.028_b0005","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.toxicon.2008.09.004","article-title":"Epidemiological, clinical characteristics and outcome of severe scorpion envenomation in South Tunisia: multivariate analysis of 951 cases","volume":"52","author":"Bouaziz","year":"2008","journal-title":"Toxicon"},{"key":"10.1016\/j.vaccine.2017.10.028_b0010","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1056\/NEJMoa0808455","article-title":"Antivenom for critically Ill children with neurotoxicity from scorpion stings","volume":"360","author":"Boyer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.028_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c7136","article-title":"Efficacy and safety of scorpion antivenom plus prazosin compared with prazosin alone for venomous scorpion (Mesobuthus tamulus) sting: randomised open label clinical trial","volume":"342","author":"Bawaskar","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2017.10.028_b0020","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/emj.2010.104158","article-title":"Meta-analysis of controlled studies on immunotherapy in severe scorpion envenomation","volume":"28","author":"Abroug","year":"2011","journal-title":"Emerg Med J"},{"key":"10.1016\/j.vaccine.2017.10.028_b0025","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0264-410X(91)90012-U","article-title":"In vivo protection against scorpion toxins by liposomal immunization","volume":"9","author":"Chavez-Olortegui","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.028_b0030","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0264-410X(97)00144-8","article-title":"In vivo protection against Androctonus australis hector scorpion toxin and venom by immunization with a synthetic analog of toxin II","volume":"15","author":"Zenouaki","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.028_b0035","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/15058","article-title":"Advances in vaccine adjuvants","volume":"17","author":"Singh","year":"1999","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2017.10.028_b0040","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","article-title":"Vaccine adjuvants: current state and future trends","volume":"82","author":"Petrovsky","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2017.10.028_b0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0169-409X(98)00008-8","article-title":"Aluminum compounds as vaccine adjuvants","volume":"32","author":"Gupta","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2017.10.028_b0050","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/jat.3314","article-title":"Dose site reactions and related findings after vaccine administration in safety studies","volume":"36","author":"Baldrick","year":"2016","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.vaccine.2017.10.028_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2013.00013","article-title":"Vaccine delivery using nanoparticles","volume":"3","author":"Gregory","year":"2013","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.vaccine.2017.10.028_b0060","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.vaccine.2016.04.035","article-title":"Development and characterization of a new carrier for vaccine delivery based on calcium-alginate nanoparticles: Safe immunoprotective approach against scorpion envenoming","volume":"34","author":"Nait Mohamed","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.028_b0065","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1586\/14760584.4.6.855","article-title":"Ensuring the quality, potency and safety of vaccines during preclinical development","volume":"4","author":"Lebron","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.10.028_b0070","doi-asserted-by":"crossref","unstructured":"Wolf JJ, Kaplanski CV, Lebron JA. Nonclinical safety assessment of vaccines and adjuvants; 2010. p. 29\u201340. https:\/\/doi.org\/10.1007\/978-1-60761-585-9_3.","DOI":"10.1007\/978-1-60761-585-9_3"},{"key":"10.1016\/j.vaccine.2017.10.028_b0075","unstructured":"World Health Organization. WHO guidelines on nonclincal evalutation of vaccines. WHO Tech Rep Ser; 2005. p. 927."},{"key":"10.1016\/j.vaccine.2017.10.028_b0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0035-9203(03)00062-2","article-title":"Epidemiological data, clinical admission gradation and biological quantification by ELISA of scorpion envenomations in Algeria: effect of immunotherapy","volume":"98","author":"Hammoudi-Triki","year":"2004","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2017.10.028_b0085","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/34923","article-title":"Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils","volume":"391","author":"Eiserich","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.10.028_b0090","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/s6070756","article-title":"Aspartate aminotransferase (AST\/GOT) and alanine aminotransferase (ALT\/GPT) detection techniques","volume":"6","author":"Huang","year":"2006","journal-title":"Sensors"},{"key":"10.1016\/j.vaccine.2017.10.028_b0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/00365517409082499","article-title":"Recommended methods for the determination of four enzymes in blood","volume":"33","author":"Keiding","year":"1974","journal-title":"Scand J Clin Lab Investig"},{"key":"10.1016\/j.vaccine.2017.10.028_b0100","article-title":"Non-clinical safety evaluations of preventative vaccines\u2014regulatory considerations","author":"Sutkwoski","year":"2003","journal-title":"Bus Brief Futur Drug Discov"},{"key":"10.1016\/j.vaccine.2017.10.028_b0105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/1091581813497405","article-title":"Preclinical safety assessment of a recombinant plague vaccine (rF1V)","volume":"32","author":"Price","year":"2013","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.vaccine.2017.10.028_b0110","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1139\/y03-115","article-title":"Effect of gamma irradiation on toxicity and immunogenicity of Androctonus australis hector venom","volume":"81","author":"Abib","year":"2003","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.vaccine.2017.10.028_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.vaccine.2017.10.028_b0120","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/annrheumdis-2011-201270","article-title":"Anti-TNF treatment blocks the induction of T cell-dependent humoral responses","volume":"72","author":"Salinas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vaccine.2017.10.028_b0125","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2217\/nnm.14.215","article-title":"Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments","volume":"10","author":"Foerster","year":"2015","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.vaccine.2017.10.028_b0130","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11250-016-0994-9","article-title":"Morphological characterization and immunohistochemical detection of the proinflammatory cytokines IL-1??, IL-17A, and TNF-?? in lung lesions associated with contagious bovine pleuropneumonia","volume":"48","author":"Sterner-Kock","year":"2016","journal-title":"Trop Anim Health Prod"},{"key":"10.1016\/j.vaccine.2017.10.028_b0135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.toxlet.2011.03.001","article-title":"Progress in understanding adjuvant immunotoxicity mechanisms","volume":"203","author":"Batista-Duharte","year":"2011","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.vaccine.2017.10.028_b0140","doi-asserted-by":"crossref","first-page":"345803","DOI":"10.1155\/2011\/345803","article-title":"Role of IL-17 and Th17 cells in liver diseases","volume":"2011","author":"Hammerich","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.vaccine.2017.10.028_b0145","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1039\/c3cs60064e","article-title":"Cytokines as biomarkers of nanoparticle immunotoxicity","volume":"42","author":"Elsabahy","year":"2013","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.vaccine.2017.10.028_b0150","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.etp.2008.03.006","article-title":"Pathophysiological effects of Androctonus australis hector scorpion venom: tissue damages and inflammatory response","volume":"60","author":"Adi-Bessalem","year":"2008","journal-title":"Exp Toxicol Pathol"},{"key":"10.1016\/j.vaccine.2017.10.028_b0155","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.vaccine.2012.01.035","article-title":"Preclinical safety assessment of recombinant botulinum vaccine A\/B (rBV A\/B)","volume":"30","author":"Shearer","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.028_b0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jat.3349","article-title":"Preclinical safety study of a recombinant Streptococcus pyogenes vaccine formulated with aluminum adjuvant","volume":"37","author":"HogenEsch","year":"2017","journal-title":"J Appl Toxicol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1731424X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1731424X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T16:08:45Z","timestamp":1535299725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1731424X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":32,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X1731424X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reactogenicity and safety assessment of an attenuated nanovaccine against scorpion envenomation: Preclinical study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}